BRU · ARGX.BR
argenx SE
€804.40+€7.80 (+0.98%)
argenx SE’s quoted price sits in the upper half of its reported 52-week range, 13.04% below the high.
Loading market information…
BRU · ONWD.BR · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:39 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Onward Medical N.V.’s quoted price sits in the lower half of its reported 52-week range, 53.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Onward Medical N.V.’s next earnings report is currently expected on Apr 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Onward Medical N.V.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Onward Medical N.V. is a medical technology company dedicated to developing innovative therapies for spinal cord injuries, operating both within the Netherlands and internationally. Among its primary offerings is ARCEX, a non-invasive, external platform. This system incorporates a wearable stimulator and a wireless programmer, designed to restore or significantly enhance hand and arm motor function for individuals living with spinal cord injuries. Complementing this is ARCIM, an implantable platform. ARCIM features an implantable pulse generator and a lead positioned near the spinal cord, empowering individuals with chronic paralysis to regain the ability to stand and walk, often with minimal or no external assistance. The company is also currently advancing the Up-LIFT Trial, a clinical study evaluating the safety and efficacy of ARCEX Therapy in restoring strength and mobility in the upper extremities of those affected by spinal cord injury. Established in 2014, Onward Medical N.V. maintains its headquarters in Eindhoven, Netherlands.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:06 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€804.40+€7.80 (+0.98%)
argenx SE’s quoted price sits in the upper half of its reported 52-week range, 13.04% below the high.
€24.28+€0.04 (+0.17%)
Koninklijke Philips N.V.’s quoted price sits in the lower half of its reported 52-week range, 12.35% below the high.
€16.46+€0.12 (+0.73%)
Ion Beam Applications S.A.’s quoted price sits in the upper half of its reported 52-week range, 7.32% below the high.
€3.86+€0.21 (+5.75%)
Hyloris Pharmaceuticals S.A.’s quoted price sits in the lower half of its reported 52-week range, 54.05% below the high.
€0.61€0.00 (0.0%)
Sequana Medical N.V.’s quoted price sits in the lower half of its reported 52-week range, 62.24% below the high.
€3.60-€0.36 (-9.09%)
European Medical Solutions’s quoted price sits in the lower half of its reported 52-week range, 34.55% below the high.
€0.21€0.00 (0.0%)
Celyad Oncology S.A.’s quoted price sits in the lower half of its reported 52-week range, 67.69% below the high.
€0.00€0.00 (0.0%)
BioSenic S.A.’s quoted price sits in the lower half of its reported 52-week range, 28.57% below the high.
